Claims

1. A tablet comprising an inner core and an outer layer, wherein the inner core is an enteric-coated tablet comprising acetylsalicylic acid, and
the outer layer comprises a potassium-competitive acid blocker free of enteric coating, and an organic acid.

2. The tablet according to claim 1 wherein the potassium-competitive acid blocker is 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (vonoprazan) or a salt thereof.

3. The tablet according to claim 1 wherein the content of acetylsalicylic acid is 70 mg - 120 mg per one tablet.

4. The tablet according to claim 1 comprising an intermediate layer between the inner core and the outer layer.

5. The tablet according to claim 4 wherein the intermediate layer comprises a water-soluble polymer.

6. The tablet according to claim 5 wherein the water-soluble polymer is one or more kinds selected from the group consisting of hydroxypropylcellulose, poly(vinyl alcohol) and hydroxypropylmethylcellulose.

~~7. The tablet according to claim 1 wherein the outer layer further comprises an organic acid.~~

~~8~~7. The tablet according to claim ~~7~~1 wherein the organic acid is fumaric acid.

~~9~~8. The tablet according to any one of claims 1 to ~~8~~7 further comprising a coating layer on the outside of the outer layer.

~~10~~9. The tablet according to claim ~~9~~8 wherein the coating layer comprises a water-soluble polymer.

~~11~~10. The tablet according to claim ~~10~~9 wherein the water-soluble polymer is one or more kinds selected from the group consisting of hydroxypropylcellulose, poly(vinyl alcohol) and hydroxypropylmethylcellulose.

~~12~~11. The tablet according to claim 1 wherein the enteric coating layer in the inner core comprises methacrylic acid copolymer LD and ethyl acrylate-methyl methacrylate copolymer.

~~13~~12. The tablet according to claim ~~12~~11 wherein the content ratio of methacrylic acid copolymer LD and ethyl acrylate-methyl methacrylate copolymer (methacrylic acid copolymer LD:ethyl acrylate-methyl methacrylate copolymer) is 85:15 - 95:5 in a weight ratio.

~~14~~13. A method for producing the tablet according to claim 1 comprising spraying a solution or suspension comprising a potassium-competitive acid blocker and an organic acid on an enteric-coated tablet comprising acetylsalicylic acid (when the aforementioned enteric-coated tablet further comprises an intermediate layer, enteric-coated tablet comprising acetylsalicylic acid and after coating the intermediate layer).